Bottom Line: The BAP cleared a massive volume of previously stalled DoD P&T Committee decisions. To protect market share and prevent access disruptions, manufacturers must act now. In late June 2026, the Department of Defense (DoD) Uniform Formulary Beneficiary Advisory Panel (BAP) held a public meeting that ended all Defense Health Agency (DHA) delays on final drug placement. The BAP systematically reviewed decisions from the eight previous Pharmacy and Therapeutics (P&T) Co

Bottom Line Recognizing federal sales patterns as real-world evidence gives manufacturers the clinical validation private payers can use to justify coverage decisions. Pharmaceutical and medical device manufacturers that treat the execution of their Federal Supply Schedule (FSS) as the finish line of a sales journey rather than the starting point of a much more valuable evidence cycle miss a critical opportunity. When a manufacturer views its FSS sales solely through a transa

Bottom Line: When commercial success is not mirrored in the federal landscape, closing the adoption gap requires a pivot from commercial tactics to a strategy of institutional integration. The strategic miscalculation among pharmaceutical and medical device manufacturers is one of institutional translation. By classifying the VA and DoD as merely large Integrated Delivery Networks (IDNs), commercial leadership teams wrongly assume federal systems obey commercial mechanics. Th

Bottom Line: The VA/DoD procurement model provides pharmaceutical manufacturers with a predictable, efficient, and simplified channel advantage by using the statutory Federal Ceiling Price (FCP) and a direct-purchase, single-payer structure that eliminates complex negotiations, post-sale rebates, and private intermediaries. The procurement model utilized by the nation's largest integrated healthcare systems, the Department of Veterans Affairs (VA) and the Department of Defens